2-{[(3R,6R)-1-{[6-chloro-4-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]carbonyl}-6-methylpiperidin-3-yl]oxy}-3-methylpyridin-4-carbonitrile | 1607428-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-{[(3R,6R)-1-{[6-chloro-4-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]carbonyl}-6-methylpiperidin-3-yl]oxy}-3-methylpyridin-4-carbonitrile
• 英文别名: US9546152, example 67；2-[(3R,6R)-1-[6-chloro-4-(triazol-2-yl)pyridine-3-carbonyl]-6-methylpiperidin-3-yl]oxy-3-methylpyridine-4-carbonitrile
• CAS: 1607428-73-8
• 化学式: C₂₁H₂₀ClN₇O₂
• 分子量: 437.889
• InChiKey: XEUXQMJVQLFIES-CZUORRHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER<br/>[FR] COMBINAISONS DE TRAMÉTINIB, PANITUMUMAB ET DABRAFÉNIB POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015087279A1

  公开（公告）日：2015-06-18

  A novel combination comprising a B-Raf inhibitor, particularly N-3-[5-(2- Amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and/or the MEK inhibitor N-3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;- 2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and panitumumab (Vectibix); pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or EGFR is beneficial, eg. cancer.

  一种新型组合物，包括一种B-Raf抑制剂，特别是N-3-[5-(2-氨基-4-嘧啶基)-2-(1,1-二甲基乙基)-1,3-噻唑-4-基]-2-氟苯基}-2,6-二氟苯磺酰胺或其药用盐，和/或MEK抑制剂N-3-[3-环丙基-5-(2-氟-4-碘苯基氨基)6,8-二甲基-2,4,7-三氧杂-3,4,6,7-四氢-2H-吡啶并[4,3-d]嘧啶-1-基]苯基}乙酰胺，或其药用盐或溶剂，以及帕尼单抗（Vectibix）；包括相同成分的药物组合物和使用这种组合物和成分治疗MEK和/或B-Raf和/或EGFR抑制对其有益的疾病状况的方法，例如癌症。
• [EN] 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE LA 2-PYRIDYLOXY-3-SUBSTITUÉE-4-NITRILE ORÉXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014066196A1

  公开（公告）日：2014-05-01

  The present invention is directed to 2-pyridyloxy-3-substituted-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-substituted-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-3-取代-4-腈化合物，其是促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶氧基-3-取代-4-腈化合物在治疗或预防神经系统和精神疾病中的用途，其中涉及促进睡眠荷尔蒙受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及使用这些制药组合物在预防或治疗涉及促进睡眠荷尔蒙受体的疾病中的用途。
• 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20150291558A1

  公开（公告）日：2015-10-15

  The present invention is directed to 2-pyridyloxy-3-substituted-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-substituted-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-3-取代-4-腈化合物，其为促进睡眠激素受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶氧基-3-取代-4-腈化合物在治疗或预防神经和精神障碍和疾病中的应用，其中促进睡眠激素受体参与其中。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗促进睡眠激素受体参与的疾病中的应用。
• Methods and pharmaceutical compositions for the treatment of cancer
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10894042B2

  公开（公告）日：2021-01-19

  The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.

  本发明涉及治疗癌症的方法和药物组合物。更具体地说，本发明涉及一种治疗有需要的受试者癌症的方法，该方法包括向受试者施用治疗有效量的至少一种 OX1R 拮抗剂。
• COMBINATION
  申请人：Glaxosmithkline LLC

  公开号：EP2911673A2

  公开（公告）日：2015-09-02